Pharmaron, a contract research organization (CRO) offering laboratory and manufacturing services for pharmaceutical and biotech research and development, has acquired Quotient Bioresearch, a UK-based CRO with more than 200 employees, focuses on integrating radiochemistry and metabolism. Part of this expertise is derived from Quotient's previous acquisition of GE Amersham's radiosynthesis business.

The acquisition strengthens the company's service portfolio, which includes broader technology platforms in chemistry, biology, DMPK (drug metabolism and pharmacokinetic) pharmacology, safety assessment and chemical and pharmaceutical development. 

Founded in 2003, Pharmaron provides drug R&D service capabilities, ranging from synthetic and medicinal chemistry, biology, DMPK, pharmacology and safety assessment to chemical & pharmaceutical development. It has more than 3,000 employees and operations in China and the US.

Source: Pharmaron